Depression in Selected Neurological Disorders

Česká verzia

Authors: I. Štětkářová ¹; J. Horáček ²
Authors place of work: Neurologická klinika 3. LF UK a FN Královské Vinohrady, Praha ¹; Psychiatrická klinika 3. LF UK a NÚDZ, Praha ²
Published in the journal: Cesk Slov Neurol N 2016; 79/112(6): 626-638
Category: Minimonography
doi: https://doi.org/10.14735/amcsnn2016626

Summary

Major depression is the most common psychiatric disorder that occurs in a number of neurological diseases. Symptoms and signs of major depression are sometimes inherent to the neurological disease, sometimes depression appears first, followed by a neurological disorder. The diagnosis and treatment of major depression has to be timely to prevent more severe and difficult to manage course of the neurological disease. Early recognition of depressive symptoms and its appropriate treatment significantly improve patients’ quality of life. Underlying mechanisms of major depression are still unknown. Interactions between many risk factors, such as biological, psychological, social and environmental are involved. The main clinical symptoms of major depression include persistent feeling of sadness, lack of interest in outside stimuli and slow psychomotor speed. Differential diagnostics have to exclude dementia and depressive syndrome induced by psychoactive substances and drugs. An acute depressive syndrome is known as a depressive phase and can be moderate or severe. Antidepressants and psychotherapy are the main treatment modalities for major depression. Therapeutic effect on the main symptoms of major depression is usually observed within 6–8 weeks after starting treatment. Major depression associated with stroke, multiple sclerosis, chronic pain, migraine, epilepsy and Parkinson’s disease is discussed in detail, including currently recommended medical treatments.

Key words:
depression – post-stroke depression – multiple sclerosis – dementia – chronic pain – migraine – epilepsy – Parkinson’s disease

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Hoschl C, Libiger J, Švestka J. Psychiatrie. Peraha: Tigis 2004.

2. Praško J, Látalová K, Sandoval A. Depresivní epizoda. In: Praško J, Látalová K, et al (eds). Psychiatrie v primární praxi. Praha: Mladá fronta a.s. 2013:408– 41.

3. Engel GL. The need for a new medical model: a challenge for biomedicine, Science 1977;196(4286):129– 36.

4. Oneib B, Sabir M, Abda N, et al. Epidemiological study of the prevalence of depressive disorders in primary health care in Morocco. J Neurosci Rural Pract 2015;6(4):477– 80. doi: 10.4103/ 0976-3147.169768.

5. Lundin A, Hal lgren M, Theobald H, et al. Validity of the 12-item version of the General Health Questionnaire in detecting depression in the general population. Public Health 2016;136:66– 74. doi: 10.1016/ j. puhe.2016.03.005.

6. Laňková J. Screening deprese v primární péči – první výsledky studie SCREEDEP. Practicus 2007;10:17– 8.

7. Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry 2011;82(8):914– 23. doi: 10.1136/ jn np.2010.230 862.

8. Štětkářová I. Deprese u neurologických onemocnění. Praha: Maxdorf 2012:1– 36.

9. Mirza SS, Wolters FJ, Swanson SA, et al. 10-year trajectories of depressive symptoms and risk of dementia: a population-based study. Lancet Psychiatry 2016;3(7):628– 35. doi: 10.1016/ 2215-0366(16)00097-3.

10. Bombardier CH, Hoekstra T, Dikmen S, et al. Depression trajectories dur ing the first year after traumatic brain injury. J Neurotrauma 2016. In pres s.

11. Anders M, Uhrová T, Roth J, et al. Depresivní porucha v neurologické praxi. Praha: Galén 2005.

12. Cherbuin N, Kim S, Anstey KJ. Dementia risk estimates as sociated with measures of depression: a systematic review and meta-analysis. BMJ Open 2015;5(12):e008853. doi: 10.1136/ bmjopen-2015-008853.

13. Krombholz R. Farmakologicky navozené deprese. Psychiat Praxi 2008;9(5):209– 12.

14. Mohr DC, Hart SL, Goldberg A. Eff ects of treatment for depression on fatigue in multiple sclerosis. Psychosom Med 2003;65(4):542– 7.

15. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301(5631):386– 9.

16. Van de Leemput J, Glatt SJ, Tsuang MT. The potential of genetic and gene expression analysis in the diagnosis of neuropsychiatric disorders. Expert Rev Mol Diagn 2016;16(6):677– 95. doi: 10.1586/ 4737159.2016.1171714.

17. Demirkan A, Lahti J, Direk N, et al. Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies. Psychol Med 2016;46(8):1613– 23. doi: 10.1017/ S0033291715 002081.

18. Donev R, Alawam K. Alterations in Gene Expression in Depression: Prospects for Personalize Patient Treatment. Protein Chem Struct Biol 2015;101:97– 124. doi: 10.1016/ bs.apcsb.2015.07.005.

19. Del l‘Os so L, Carmas si C, Mucci F, et al. Depression, Serotonin and Tryptophan. Curr Pharm Des 2016;22(8): 949– 54.

20. Fakhoury M. New insights into the neurobiological mechanisms of major depressive disorders. Gen Hosp Psychiatry 2015;37(2):172– 7. doi: 10.1016/ j.genhosppsych. 2015.01.005.

21. Jeon SW, Kim Y. Neuroinfl am mation and cytokine abnormality in major depression: cause or consequence in that il lnes s? World J Psychiatry 2016;6(3):283– 93. doi: 10.5498/ wjp.v6.i3.283.

22. Praško J, Látalová K, Sandoval A. Depresivní epizoda. In: Praško J, Látalová K. et al (eds). Psychiatrie v primární praxi. Praha: Mladá fronta a.s. 2013:408– 41.

23. Raboch J, Laňková J. Deprese. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Praha: CDP-PL 2008:16.

24. Štětkářová I, Horáček J. Deprese u neurologických onemocnění. In: Štětkářová I. et al (eds). Moderní farmakoterapie v neurologii. Praha: Maxdorf 2015:327– 38.

25. Blumberger DM, Hsu JH, Daskalakis ZJ. A review of brain stimulati on treatments for late-life depression. Curr Treat Options Psychiatry 2015;2(4):413– 21.

26. Palm U, Hasan A, Strube W, et al. tDCS for the treatment of depression: a comprehensive review. Eur Arch Psychiatry Clin Neurosci 2016. Inpres s.

27. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746– 58. doi: 10.1016/ S0140-6736 (09)60046-5.

28. Ken nedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depres sive disorder: a meta analysis. Curr Med Res Opin 2009;25(1):161– 75. doi: 10.1185/ 03007990802622726 .

29. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry 2016;173(3):221– 31. doi: 10.1176/ appi.ajp.2015.15030363.

30. Göthe F, Enache D, Wahlund LO, et al. Cerebrovascular diseases and depres sion: epidemiology, mechanisms and treatment. Panminerva Med 2012;54(3):161– 70.

31. Salter KL, Foley NC, Zhu L, et al. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis 2012;22(8):1243– 51. doi: 10.1016/ j.jstrokecerebrovasdis.2012.03.013

32. Ayerbe L, Ayis S, Crichton S, et al. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke 2013;4(4): 1015– 20. doi: 10.1161/ STROKEAHA.111.679340.

33. Nishiyama Y, Komaba Y, Ueda M, et al. Early depressive symp toms after ischemic stroke are as sociated with a left lenticulocapsular area lesion. J Stroke Cerebrovasc Dis 2010;19(3):184– 9. doi: 10.1016/ j.jstrokecerebrovasdis. 2009.04.002.

34. Singh A, Black SE, Herrmann N, et al. Functional and neuroanatomic correlations in poststroke depression: the Sun nybrook Stroke Study. Stroke 2000;31(3): 637– 44.

35. Hirata S, Ovbiagele B, Markovic D, et al. Key factors associated with major depression in a national sample of stroke survivors. J Stroke Cerebrovasc Dis 2016;25(5):1090– 5. doi: 10.1016/ j.jstrokecerebrovasdis. 2015.12.042.

36. De Ryck A, Brouns R, Fransen E, et al. A prospective study on the prevalence and risk factors of poststroke depression. Cerebrovasc Dis Extra 2013;3(1):1– 13. doi: 10.1159/ 000345557.

37. Wal lin MT, Wilken JA, Turner AP, et al. Depression and multiple sclerosis: review of a lethal combination. J Rehabil Res Dev 2006;43(1):45– 62.

38. Havrdová E, et al. Roztroušená skleróza. Praha: Mladá fronta 2013.

39. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62(4):586– 90.

40. Görnerová N. Sclerosis multiplex a psychiatrická komorbidita. Psychiatrie 2014;18(4):177– 85.

41. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67(7):1242– 9.

42. Papar rigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, aff ect and behaviour. Int Rev Psychiatry 2010;22(1):14– 21. doi: 10.3109/ 09540261003589 323.

43. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005;11(3):328– 37.

44. Vachová M, Dušánková J, Zámečník L. Symptomatická léčba roztroušené sklerózy. Neurol Praxi 2008;9(4):226– 31.

45. Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expres sive group psychotherapy, and sertraline for the treatment of depression in multiple

sclerosis. J Consult Clin Psychol 2001;69(6):942– 9.

46. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol 2012;2012:427102. doi: 10.5402/ 2012/ 427102.

47. Mohr DC, Epstein L, Luks TL, et al. Brain lesion volume and neuropsychological function predictefficacy of treatment for depression in multiple sclerosis. J Consult Clin Psychol 2003;71(6):1017– 24.

48. Apkarian AV, Sosa Y, Sonty S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci 2004;24(46):10410– 5.

49. Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature ag ing of the brain? J Neurosci 2007;27(15):4004– 7.

50. Thaler KJ, Morgan LC, Van Noord M, et al. Comparative effectiveness of second-generation antidepressants for accompany ing anxiety, insomnia, and pain in depressed patients: a systematic review. Depress Anxiety 2012;29(6):495– 505. doi: 10.1002/ da.21951.

51. Arnold LM, Clauw D, Wang F, et al. Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-control led trial. J Rheumatol 2010;37:2578– 86. doi: 10.3899/ jrheum.100 365.

52. Mann ing JS, Jackson WC. Depression, pain, and comorbid medical conditions. J Clin Psychiatry 2013;74(2):e03. doi: 10.4088/ JCP.12049vs3c.

53. Medová E, Štětkářová I. Primární bolesti hlavy a obličeje. In: Štětkářová I, et al (eds). Moderní farmakoterapie v neurologii. Praha: Maxdorf 2015:108– 24.

54. Antonaci F, Nappi G, Gal li F, et al. Migraine and psychiatric comorbidity: a review of clinical findings. J Headache Pain 2011;12(2):115– 25. doi: 10.1007/ s10194-010- 0282-4.

55. Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL. Migraine: current concepts and emerging therapies. Vascul Pharmacol 2005;43(3):176– 87.

56. Evers S. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 2008;9(15):2565– 73. doi: 10.1517/ 14656566.9.15.2565.

57. Kogut SJ. Do triptan antimigraine medications interact with SSRI/ SNRI antidepres sants? What does your decision support system say? J Manag Care Pharm 2011;17(7):547– 51.

58. Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol 2016;15(1):106– 15. doi: 10.1016/ S1474- 4422(15)00225-2.

59. Błaszczyk B, Czuczwar SJ. Epilepsy coexist ing with depression. Pharmacol Rep 2016;68(5):1084– 92. doi: 10.1016/ j.pharep.2016.06.011.

60. Johannessen Landmark C, Henning O, Johannessen SI. Proconvulsant effects of antidepres sants – what is the current evidence? Epilepsy Behav 2016;61(6):287– 91. doi: 10.1016/ j.yebeh.2016.01.029.

61. Cooney JW, Stacy M. Neuropsychiatric issues in Parkinson‘s disease. Curr Neurol Neurosci Rep 2016;16(5):49. doi: 10.1007/ s11910-016-0647-4.

62. Wen MC, Chan LL, Tan LC, et al. Depression, anxiety, and apathy in Parkinson‘s disease: insights from neuroimag ing studies. Eur J Neurol 2016;23(6):1001– 19. doi: 10.1111/ ene.13002.

63. Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson‘s disease. Parkinsons Dis 2015;2015:609428. doi: 10.1155/ 2015/ 609428.

64. Aarsland D, Kramberger MG. Neuropsychiatric Symptoms in Parkinson‘s Disease. J Parkinsons Dis 2015;5(3):659– 67. doi: 10.3233/ JPD-150604.

65. Xie CL, Chen J, Wang XD, et al. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson’s disease: a meta-analysis of randomized controlled clinical trials. Neurol Sci 2015;36(10):1751– 61. doi: 10.1007/ s10072-015-2345-4.